A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer.

ABSTRACT:

Background

To evaluate the efficacy of cetuximab combined with modified FOLFIRI (mFOLFIRI) as a second-line treatment in metastatic gastric cancer patients and to identify potential biomarkers of clinical outcomes.

Methods

All 61 patients received an initial intravenous (IV) dose of cetuximab (400 mg/m²) and weekly doses (250 mg/m²) thereafter, starting on day 1. On day 2 of each 14-day period, patients received IV irinotecan (180 mg/m²), leucovorin (200 mg/m²), and an IV bolus dose of 5-FU (400 mg/m²) followed by a continuous infusion of 5-FU (2400 mg/m²) for 46 h. The primary endpoint was time-to-progression (TTP).

Results

The response rate (RR) was 33.3% among 54 evaluable patients. In the intention-

SUBMITTER: Liu X 

PROVIDER: S-EPMC5348753 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature